174 related articles for article (PubMed ID: 31074707)
1. The emergence of follow-on disease-modifying therapies for multiple sclerosis.
Moss BP; Cohen JA
Mult Scler; 2019 Oct; 25(12):1560-1565. PubMed ID: 31074707
[TBL] [Abstract][Full Text] [Related]
2. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J
J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
[TBL] [Abstract][Full Text] [Related]
3. Considerations in the development of generic disease therapies for multiple sclerosis.
Hua LH; Cohen JA
Neurol Clin Pract; 2016 Aug; 6(4):369-376. PubMed ID: 27574572
[TBL] [Abstract][Full Text] [Related]
4. Two decades of glatiramer acetate: From initial discovery to the current development of generics.
Weinstock-Guttman B; Nair KV; Glajch JL; Ganguly TC; Kantor D
J Neurol Sci; 2017 May; 376():255-259. PubMed ID: 28431621
[TBL] [Abstract][Full Text] [Related]
5. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
[TBL] [Abstract][Full Text] [Related]
6. Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis.
Bourdette D; Hartung D
JAMA Neurol; 2015 Dec; 72(12):1411-3. PubMed ID: 26457848
[No Abstract] [Full Text] [Related]
7. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
Sørensen PS
Nat Rev Neurol; 2016 Jan; 12(1):5-6. PubMed ID: 26635211
[TBL] [Abstract][Full Text] [Related]
8. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
9. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
10. Biological and nonbiological complex drugs for multiple sclerosis in Latin America: regulations and risk management.
Carrá A; Macías Islas MA; Tarulla A; Bichuetti DB; Finkelsztejn A; Fragoso YD; Árcega-Revilla R; Cárcamo Rodríguez C; Durán JC; Bonitto JG; León R; Oehninger Gatti C; Orozco G; Vizcarra Escobar D
Expert Rev Neurother; 2015 Jun; 15(6):597-600. PubMed ID: 25924772
[TBL] [Abstract][Full Text] [Related]
11. [A place of first-line drugs in treatment of multiple sclerosis].
Kasatkin DS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis disease-modifying therapy and pregnancy.
Miller AE
Mult Scler; 2016 May; 22(6):715-6. PubMed ID: 27207870
[No Abstract] [Full Text] [Related]
13. Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes.
Borchard G; Crommelin DJA
Expert Opin Drug Deliv; 2018 Mar; 15(3):247-259. PubMed ID: 29241378
[TBL] [Abstract][Full Text] [Related]
14. Follow-on products for treatment of multiple sclerosis in Latin America: An update.
Correale J
J Neurol Sci; 2017 Oct; 381():153-159. PubMed ID: 28991670
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of equivalence of a generic glatiramer acetate (Glatopa™).
Anderson J; Bell C; Bishop J; Capila I; Ganguly T; Glajch J; Iyer M; Kaundinya G; Lansing J; Pradines J; Prescott J; Cohen BA; Kantor D; Sachleben R
J Neurol Sci; 2015 Dec; 359(1-2):24-34. PubMed ID: 26671082
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
Jongen PJ; Lemmens WA; Hoogervorst EL; Donders R
Health Qual Life Outcomes; 2017 Mar; 15(1):50. PubMed ID: 28292329
[TBL] [Abstract][Full Text] [Related]
17. Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis.
Hartung DM; Johnston KA; Geddes J; Bourdette DN
Neurology; 2020 Mar; 94(13):e1407-e1414. PubMed ID: 31941796
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
Tsareva E; Kulakova O; Boyko A; Favorova O
Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
[TBL] [Abstract][Full Text] [Related]
19. Spasticity in multiple sclerosis and role of glatiramer acetate treatment.
Meca-Lallana JE; Hernández-Clares R; Carreón-Guarnizo E
Brain Behav; 2015 Sep; 5(9):e00367. PubMed ID: 26445705
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
